Rossari Biotech Ltd Q3 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/871me4djtc1nuuko4l1fao3w.pdf

Key Takeaways


The Guidance Reset

Ketan Sablok: "The way the second half has panned out, I don't think we are going to hit that number of Rs. 2,000 crore. Going by the current run rate, I think we should be closer to about Rs. 1,650-1,700 crore, around that number."

Margin & Mix Shift

Edward Menezes: "All our new projects are always targeted to 20% EBITDA... most of the projects that we've started would be at least 30% gross margins and about 18% to 20% EBITDA."

Subsidiary Performance & Integration


Standalone & Segment Dynamics

Sunil Chari: "Historically, agro season is strong in the first two quarters for last 30 years for Unitop. So, the third quarter is always a little weak. Therefore, the third and fourth quarters are weak for Unitop."

Competitive Positioning & R&D

Edward Menezes: "If you ask somebody in the market, then you will notice that Rossari can really deliver solutions and products to the market much faster than most of our competitors."

Guidance & Commitments

CommitmentSpecificsTimeline
FY23 top lineClose around ₹1,650–1,700 croreFY23 (year ending Mar 2023)
FY23 EBITDA₹220–230 croreFY23
FY24 top-line growthAt least 15–20% with better margin growthFY24
EBITDA margin recoveryMove toward 15% next year, 16–17% over two yearsFY24 exit / FY25
Tristar export normalizationReturn to quarterly run rateQ4 FY23
Unitop volume pickupRecovery from seasonal weaknessMid-Feb 2023 onwards
Lost-customer offsetEntirely negate the business lossNext couple of quarters
Textile demand recoveryPickup in demandMay–June 2023 onwards
HPPC doublingDouble the business3–4 years
AHN doublingDouble the business2–3 years
Overall sales doublingDouble consolidated sales3–4 years
FY24 CAPEXNot more than ₹30–40 croreFY24

Key Metrics

MetricQ3 FY23
Consolidated revenue₹389 crore, vs ₹428 crore in Q3 FY22
Standalone revenue₹237 crore, vs ₹268 crore in Q3 FY22
HPPC revenue₹271 crore, 69.7% of consolidated revenue
TSC revenue₹89.5 crore, 23% of consolidated revenue
AHN revenue₹28.6 crore, 7.3% of consolidated revenue
Consolidated gross margin30%, vs 25% in Q3 FY22
Standalone gross margin29%, vs 22% in Q3 FY22
Consolidated EBITDA margin14%, vs 11% in Q3 FY22
Consolidated EBITDA₹54.2 crore, vs ₹56.5 crore in Q2 FY23
Consolidated PAT₹25.7 crore, vs ₹23.9 crore in Q2 FY23
Standalone EBITDA₹32 crore, vs ₹28 crore in Q2 FY23
Standalone PAT₹17.5 crore, vs ₹16.4 crore in Q2 FY23
FY23 revenue guidance (revised)₹1,650–1,700 crore, down from earlier ₹2,000 crore
FY23 EBITDA guidance (revised)₹220–230 crore, down from earlier ₹250 crore
FY24 top-line growth outlook15% to 20%, with better margin growth
EBITDA margin target over next 2 years16%–17%, moving up from ~13% in FY23
Capacity utilization~55%, with headroom to nearly double turnover
Consolidated exports (9M FY23)~24% of sales
Subsidiary QoQ revenue degrowth~9% in Q3 over Q2
CAPEX spends (9M FY23)₹5–10 crore
FY24 expected CAPEXnot more than ₹30–40 crore
HPPC business doubling timeline3 to 4 years
AHN business doubling timeline2 to 3 years
Textiles business doubling timeline4 to 5 years
New project EBITDA target18% to 20%, with at least 30% gross margin
AHN historical gross marginupwards of 50%